Table 1.
Patient characteristics and transplant outcomes
| Characteristics | Patients= 346 |
|---|---|
| Median age, years (range) | 56 (18–73) |
| Gender Male, n (%) | 186 (54) |
| Female donor to male recipient | 62 (18) |
| Underlying disease, n (%) | |
| AML | 244 (71) |
| MDS | 102 (29) |
| Disease status for acute leukemia*, n (%) | |
| CR1 | 158 (65) |
| CR2–3 | 86 (35) |
| Disease Risk Index**, n(%) | |
| Low | 16 (5%) |
| Intermediate | 285 (82%) |
| High | 43 (12%) |
| Very High | 1 (<1%) |
| Donor type, n (%) | |
| Related HLA identical | 125 (36) |
| Related non-HLA identical | 7 (2) |
| Matched unrelated | 129 (38) |
| Mismatched unrelated | 85 (25) |
| Conditioning regimen***, n (%) | |
| TBI-based | 118 (34) |
| Chemotherapy-based | 228 (66) |
| ATG, n (%) **** | |
| Rabbit 2.5–7.5 mg/kg | 268 (77) |
| Equine 30–45 mg/kg | 48 (14) |
| No ATG | 27 (8) |
|
Infused cell dose CD34+ ×106/kg, median (range) |
7.6 (1.5–28.8) |
| Previous auto-HCT, n (%) | 15 (4) |
| T-cell depletion method, n (%) | |
| Clinimacs® | 152 (44) |
| Isolex | 194 (56) |
| Patients comorbidities*****, n (%) | |
| Pulmonary severe / moderate | 45 (13) / 108 (31) |
| Psychiatric disturbance | 70 (20) |
| Hepatic moderate-severe / mild | 8 (2) / 54 (16) |
| Previous malignancy | 61 (18) |
| Obesity | 28 (8) |
| Cardiac | 30 (9) |
| Infection | 24 (7) |
| Diabetes | 21 (6) |
Abbreviations: AML, acute myeloid leukemia; MDS, myelodysplastic syndrome; n, number; HLA, human leukocyte antigen; CR, complete remission; TBI, total body irradiation; HCT, hematopoietic cell transplantation
*
Percentages over total number of AML patients (n=244).
**
Since the DRI does not account for mixed phenotype acute leukemia, 1 patient could not be categorized.
***
For detailed information on conditioning regimen see Methods.
****
3 patients included in a clinical trial received rabbit ATG 2.5mg/kg in combination of equine ATG 15mg/kg
*****
Only comorbidities present in ≥ 5% of the patients are shown.